Skip to main content
SpringerLink
Log in

Iron as a Drug and Drug–Drug Interactions

  • Chapter
  • First Online:
Iron Deficiency and Overload

Part of the book series: Nutrition and Health ((NH))

  • 1698 Accesses

Summary

• Bioavailabiltiy of oral iron may be enhanced in the presence of reducing agents such as ascorbic acid.

• All commercially available iron salts are effective in the treatment of iron deficiency.

• Administration of oral iron should be separated from other medications by at least 1–2 hours.

• The use of iron dextran is not attractive compared to other IV iron preparations because of its side effect profile.

• Infusion-related side effects such as hypotension can be alleviated by slowing the rate of administration of IV iron preparations.

• Acute iron toxicity should be treated promptly with gastric lavage and supportive care.

• Chronic iron toxicity can result in significant organ damage and is treated with chelation agents such as deferoxamine, deferiprone, and deferasirox.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams, P. C. (2006). Review article: The modern diagnosis and management of haemochromatosis. Alimentary Pharmacology and Therapeutics, 23, 1681–1691.

    Article  PubMed  CAS  Google Scholar 

  • Adamson, J. W. (1999, August). Normal iron physiology. Seminars in Dialysis, 12(4), 219–223.

    Article  Google Scholar 

  • American Regent, Inc. (2003, June). Venofer (package insert). Shirley, NY.

    Google Scholar 

  • Anderson, G. J. (2007). Mechanisms of iron loading and toxicity. American Journal of Hematology, 82, 1128–1131.

    Article  PubMed  CAS  Google Scholar 

  • Anderson, K. J., & Rivers, R. P. A. (1992). Desferrioxamine in acute iron poisoning. Lancet, 339, 1601–1602.

    Article  Google Scholar 

  • Andrews, N. C. (1999). Disorders of iron metabolism. New England Journal of Medicine, 341(26), 1986–1995.

    Article  PubMed  CAS  Google Scholar 

  • Andrews, N. C., & Schmidt, P. J. (2007). Iron homeostasis. Annual Review of Physiology, 69, 69–85.

    Article  PubMed  CAS  Google Scholar 

  • Banner, W., & Tong, T. G. (1986). Iron poisoning. Pediatric Clinics of North America, 33, 393–409.

    PubMed  Google Scholar 

  • Barton, J. C., McDonnell, S. M., & Adams, P. C. (1998). Management of hemochromatosis. Annals of Internal Medicine, 129(11S), 932–939.

    PubMed  CAS  Google Scholar 

  • Beard, J. L. (2001). Iron biology in immune function, muscle metabolism and neuronal functioning. The Journal of Nutrition, 131(2), 568S–580S.

    PubMed  CAS  Google Scholar 

  • Benson, B., & Cheney, K. (1992). Survival after a severe iron poisoning treated with high dose deferoxamine (DFO) therapy. Veterinary and Human Toxicology, 34, 329.

    Google Scholar 

  • Beutler, E., Hoffbrand, A. V., & Cook, J. D. (2003). Iron deficiency and overload. Hematology – American Society of Hematology Educational Program, Washington, DC, pp. 40–61.

    Google Scholar 

  • Brittenham, G. M., & Badman, D. G. (2003). Noninvasive measurement of iron: Report of an NIDDK workshop. Blood, 101, 15–19.

    Google Scholar 

  • Buja, L. M., & Roberts, W. C. (1971). Iron in the heart. Etiology and clinical significance. American Journal of Medicine, 51(2), 209–221.

    Article  PubMed  CAS  Google Scholar 

  • Burkhart, K. K., Kulig, K. W., & Hammond, K. B. (1991). The rise in the total iron-binding capacity after iron overdose. Annals of Emergency Medicine, 20, 532–535.

    Article  PubMed  CAS  Google Scholar 

  • Campbell, N., Paddock, V., & Sundaram, R. (1988, April). Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate. Clinical Pharmacology and Therapeutics, 43(4), 381–386.

    Article  PubMed  CAS  Google Scholar 

  • Campbell, N. R., & Hasinoff, B. (1989, March). Ferrous sulfate reduces levodopa bioavailability: Chelation as a possible mechanism. Clinical Pharmacology and Therapeutics, 45(3), 220–225.

    Article  PubMed  CAS  Google Scholar 

  • Campbell, N. R., Hasinoff, B. B., Stalts, H., Rao, B., & Wong, N. C. (1992, December 15). Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Annals of Internal Medicine, 117(12), 1010–1013.

    PubMed  CAS  Google Scholar 

  • Cappellini, M. D. (2005). Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Practices and Research in Clinical Hematology, 18(2), 289–298.

    Article  CAS  Google Scholar 

  • Cogswell, M. E., McDonnell, S. M., Khoury, M. J., Franks, A. L., Burke, W., & Brittenham, G. (1998). Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening. Annals of Internal Medicine, 129(11), 971–979.

    PubMed  CAS  Google Scholar 

  • Cohen, A. R., Galanello, R., & Piga, A. (2000). Safety profile of the oral iron chelator deferiprone: A multicentre study. British Journal of Haematology, 108, 305–312.

    Article  PubMed  CAS  Google Scholar 

  • Carbonyl iron. (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Cook, J. D., Dassenko, S. A., & Whittaker, P. (1991, January). Calcium supplementation: Effect on iron absorption. American Journal of Clinical Nutrition, 53(1), 106–111.

    PubMed  CAS  Google Scholar 

  • Cook, J. D. (2000). Hemochromatosis. In R. E. Rakel (Ed.), Conn’s current therapy (pp. 404–406). Philadelphia: WB Saunders.

    Google Scholar 

  • Crosby, J. D. (1984, March). The rationale for treating iron deficiency anemia. Archives of Internal Medicine, 144(3), 471–472.

    Article  PubMed  CAS  Google Scholar 

  • Deppermann, K. M., & Lode, H. (1993). Fluoroquinolones: Interaction profile during enteral absorption. Drugs, 45(Suppl. 3), 65–72.

    Article  PubMed  Google Scholar 

  • deVirgiliis, S., Sanna, G., & Cornacchia, G. (1980). Serum ferritin, liver iron stores, and liver histology in children with thalassemia. Archives of Diseases in Childhood, 55, 43–45.

    Article  CAS  Google Scholar 

  • Ehlers, K. H., Levin, A. R., Markenson, A. L., Marcus, J. R., Klein, A. A., Hilgartner, M. W., et al. (1980). Longitudinal study of cardiac function in thalassemia major. Annals of the New York Academy of Sciences, 344, 397–404.

    Article  PubMed  CAS  Google Scholar 

  • Felitti, V. J., & Beutler, E. (1999). New developments in hereditary hemochromatosis. American Journal of Medical Science, 318(4), 257–268.

    Article  CAS  Google Scholar 

  • Ferrous aspartate. (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Ferrous fumarate. (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Ferrous gluconate. (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Ferrous sulfate. (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Franchini, M. (2005). Recent acquisitions in the management of iron overload. Annals of Hematology, 84, 640–645.

    Article  PubMed  CAS  Google Scholar 

  • Gelone, D. K., Park, J. M., & Lake, K. D. (2007, September). Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. Pharmacotherapy, 27(9), 1272–1278.

    Article  PubMed  CAS  Google Scholar 

  • Gervitz, N. R., & Wasserman, L. R. (1966). The measurement of iron and iron-binding capacity in plasma containing deferoxamine. Journal of Pediatrics, 68, 802–804.

    Article  Google Scholar 

  • Gleason, W. A., de Mello, D. E., & de Castro, F. J. (1979). Acute hepatic failure in severe iron poisoning. Journal of Pediatrics, 95, 138–140.

    Article  PubMed  Google Scholar 

  • Golubov, J., Flanagan, P., & Adams, P. (1991, April). Inhibition of iron absorption by omeprazole in rat model. Digestive Diseases and Sciences, 36(4), 405–408.

    Article  PubMed  CAS  Google Scholar 

  • Greene, R. J., Hall, A. D., & Hider, R. C. (1990, July). The interaction of orally administered iron with levodopa and methyldopa therapy. The Journal of Pharmacy and Pharmacology, 42(7), 502–504.

    Article  PubMed  CAS  Google Scholar 

  • Harchelroad, F., & Rice, S. (1992). Iron dextran: Treatment or overdose? Veterinary and Human Toxicology, 34, 329.

    Google Scholar 

  • Harju, E. (1989, August). Clinical pharmacokinetics of iron preparations. Clinical Pharmacokinetics, 17(2), 69–89.

    Article  PubMed  CAS  Google Scholar 

  • Heeney, M. M., & Andrews, N. C. (2004). Iron homeostasis and inherited iron overload disorders: An overview. Hematology – Oncology Clinics of North America, 18(6), 1379–1403.

    Article  Google Scholar 

  • Helfer, R. E., & Rodgerson, D. O. (1966). The effect of deferoxamine on the determination of serum iron and iron-binding capacity. Journal of Pediatrics, 68, 804–806.

    Article  PubMed  CAS  Google Scholar 

  • Hoffbrand, A. V. (2005). Deferiprone therapy for transfusional iron overload. Best Practice and Research in Clinical Hematology, 18(2), 299–317.

    Article  Google Scholar 

  • Howland, M. A. (1996). Risks of parenteral deferoxamine for acute iron poisoning. Clinical Toxicology, 34, 491–497.

    Article  PubMed  CAS  Google Scholar 

  • Hristova, E. N., & Henry, J. B. (2001). Metabolic intermediates, inorganic ions and biochemical markers of bone metabolism. In J. B. Henry (Ed.), Clinical diagnosis and management of laboratory methods (pp. 180–191). Philadelphia: WB Saunders.

    Google Scholar 

  • Iron (management treatment protocol). (n.d.). POISINDEX® Retrieved January 2, 2008, from http://www.thomsonhc.com. Greenwood Village, CO: Thomson Healthcare.

  • Iron-containing products (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Jacobs, J., Greene, H., & Gendel, B. R. (1965). Acute iron intoxication. New England Journal of Medicine, 273, 1124–1127.

    Article  PubMed  CAS  Google Scholar 

  • Jaeger, R. W., De Castro, F. J., & Barry, R. C. (1981). Radiopacity of drugs and plants in vitro – Limited usefulness. Veterinary and Human Toxicology, 23, 2–4.

    PubMed  CAS  Google Scholar 

  • Jensen, P. D., Jensen F. T., Christensen, T., Heickendorff, L., Jensen, L. G., & Ellegaard, J. (2001). Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. Magnetic Resonance Materials in Physics, Biology and Medicine, 12, 153–166.

    CAS  Google Scholar 

  • Kontoghiorghes, G. J., Eracleous, E., Economides, C., & Kolnagou, A. (2005). Advances in iron overload therapies: Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, LINAII and their combinations. Current Medicinal Chemistry, 12, 2663–2681.

    Article  PubMed  CAS  Google Scholar 

  • Kowdley, K. V., & Kaplan, M. M. (1998). Iron-chelation therapy with oral deferiprone – Toxicity or lack of efficacy. New England Journal of Medicine, 339, 468–469.

    Article  PubMed  CAS  Google Scholar 

  • Kushner, J. P., Porter, J. P., & Olivieri, N. F. (2001). Secondary iron overload. Hematology, 47–61.

    Google Scholar 

  • Lehto, P., Kivisto, K. T., & Neuvonen, P. J. (1994, January). The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. British Journal of Clinical Pharmacology, 37(1), 82–85.

    Article  PubMed  CAS  Google Scholar 

  • Leyden, J. J. (1985, February). Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. Journal of the American Academy of Dermatology, 12, 308–312.

    Article  PubMed  CAS  Google Scholar 

  • Ling, L. J., Hornfeldt, C. S., & Winter, J. P. (1991). Absorption of iron after experimental overdose of chewable vitamins. American Journal of Emergency Medicine, 9, 24–26.

    PubMed  CAS  Google Scholar 

  • Lorenz, M., Wolzt, M., Weigel, G., Puttinger, H., Horl, W. H., Fodinger, M., et al. (2004, June). Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. American Journal of Kidney Diseases, 43(6), 1098–1103.

    Article  PubMed  CAS  Google Scholar 

  • Manoguerra, A. S., Erdman, A. R., & Booze, L. L. (2005). Iron ingestion: An evidence based consensus guideline for out-of-hospital management. Clinical Toxicology, 43(6), 553–570.

    Article  PubMed  CAS  Google Scholar 

  • Neilsen, P., Engelhardt, R., Dullmann, J., & Fischer, R. (2002). Non-invasive liver iron quantification by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells, Molecules and Diseases, 29, 451–458.

    Article  Google Scholar 

  • Neuvonen, P. J. (1976). Interactions with the absorption of tetracyclines. Drugs, 11(1), 45–54.

    Article  PubMed  CAS  Google Scholar 

  • Ng, R. C. W., Perry, K., & Martin, D. J. (1979). Iron poisoning: Assessment of radiography in diagnosis and management. Clinical Pediatrics, 18, 614–616.

    Article  PubMed  CAS  Google Scholar 

  • Novartis. (2007a, November). Desferal (package insert). East Hanover, NJ.

    Google Scholar 

  • Novartis. (2007b, December). Exjade (package insert). East Hanover, NJ.

    Google Scholar 

  • Olivares, M., Pizarro, F., & Ruz, M. (2007, April). New insights about iron bioavailability inhibition by zinc. Nutrition, 23(4), 292–295.

    Article  PubMed  CAS  Google Scholar 

  • Olivieri, N. F. (1999). The beta-thalassemias. New England Journal of Medicine, 341, 99–109.

    Article  PubMed  CAS  Google Scholar 

  • Olivieri, N. F., DeSilva, S., & Premawardena, A. (2000). Iron overload and iron-chelating therapy in hemoglobin E-β Thalassemia. Journal of Pediatric Hematology Oncology, 22, 593–597.

    Article  CAS  Google Scholar 

  • O'Neil-Cutting, M. A., & Crosby, W. H. (1986, March 21). The effect of antacids on the absorption of simultaneously ingested iron. The Journal of the American Medical Association, 255(11), 1468–1470.

    Article  Google Scholar 

  • Ooi, G. C., Khong, P. L., & Chan, G. C. F. (2004). Magnetic resonance screening of iron status in transfusion-dependent β-thalassemia patients. British Journal of Haematology, 124, 385–390.

    Article  PubMed  CAS  Google Scholar 

  • Oral Iron Preparations (n.d.), Lexicomp online. Retrieved February 12, 2008, from http://www.crlonline.com. Hudson, OH: Lexicomp, Inc.

  • Oski, F. A. (1993, July 15). Iron deficiency in infancy and childhood. New England Journal of Medicine, 329(3), 190–193.

    Article  PubMed  CAS  Google Scholar 

  • Osman, M. A., Patel, R. B., Schuna, A., Sundstrom, W. R., & Welling, P. G. (1983, April). Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clinical Pharmacology and Therapeutics, 33(4), 465–470.

    Article  PubMed  CAS  Google Scholar 

  • Pakbaz, Z., Fischer, R., & Treadwell, M. (2005). A simple model to assess and improve adherence to iron-chelation therapy with deferoxamine in patients with thalassemia. Annals of the New York Academy of Science, 1054, 486–491.

    Article  CAS  Google Scholar 

  • Perrone, J. (2006). Iron. In L. R. Goldfrank (Ed.), Goldfrank’s toxicologic emergencies (pp. 548–562). New York: McGraw Hill.

    Google Scholar 

  • Polysaccharide iron complex. (2008). Drug facts and comparisons 4.0. Retrieved February 12, 2008, from http://online.factsandcomparisons.com. Indy, IN: Wolters Kluwer Health, Inc.

  • Porter, J. B. (2001). Practical management of iron overload. British Journal of Haematology, 115, 239–252.

    Article  PubMed  CAS  Google Scholar 

  • Porter, J. B. (2005). Monitoring and treatment of iron overload: State of the art and new approaches. Seminars in Hematology, 42, S14–S18.

    Article  PubMed  CAS  Google Scholar 

  • Powell, L. W., George, D. K., McDonnell, S. M., & Kowdley, K. V. (1998). Diagnosis of hemochromatosis. Annals of Internal Medicine, 129(11), 925–931.

    PubMed  CAS  Google Scholar 

  • Powell, L. W. (2002). Hereditary hemochromatosis and iron overload diseases. Journal of Gastroenterology and Hepatology, 7, S191–S195.

    Article  Google Scholar 

  • Proudfoot, A. T., Simpson, D., & Dyson, E. H. (1986). Management of acute iron poisoning. Medical Toxicology, 1, 83–100.

    PubMed  CAS  Google Scholar 

  • Schaefer, J. P., Tam, Y., Hasinoff, B. B., Tawfik, S., Peng, Y., Reimche, L., et al. (1998, October). Ferrous sulphate interacts with captopril. British Journal of Clinical Pharmacology, 46(4), 377–381.

    Article  PubMed  CAS  Google Scholar 

  • Schafer, A. I., & Bunn, H. F. (2001). Iron-deficiency and iron-loading anemias. In R. G. Petersdorf, J. B. Martin, & Braunwald, E. (Eds.), Harrison’s principles of internal medicine (pp. 1848–1853). New York: McGraw-Hill.

    Google Scholar 

  • Schauben, J. L., Augenstein, W. L., & Cox, J. (1990). Iron poisoning: Report of three cases and a review of therapeutic intervention. Journal of Emergency Medicine, 8, 309–319.

    Google Scholar 

  • Schilsky, M. L., & Fink, S. (2006). Inherited metabolic liver disease. Current Opinions in Gastroenterology, 22, 215–222.

    Article  Google Scholar 

  • Siff, J. E., Meldon, S. W., & Tomassoni, A. J. (1999). Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose. Annals of Emergency Medicine, 33, 73–76.

    Article  PubMed  CAS  Google Scholar 

  • Silverstein, S. B., & Rodgers, G. M. (2004, May). Parenteral iron therapy options. American Journal of Hematology, 76(1), 74–78.

    Article  PubMed  CAS  Google Scholar 

  • Sunder-Plassmann, G., & Hörl, W. H. (1999, August). Comparative look at intravenous iron agents: Pharmacology, efficacy, and safety of iron dextran, iron saccharate, and ferric gluconate. Seminars in Dialysis, 12(4), 243–248.

    Article  Google Scholar 

  • Stumpf, J. L. (2007). Deferasirox. American Journal of Health-Systems Pharmacists, 64, 606–616.

    Article  CAS  Google Scholar 

  • Tam, T. F., Leung-Toung, R., Li, W., Wang, Y., Khashayer, K., & Spino, M. (2003). Iron chelator research: Past, present and future. Current Medicinal Chemistry, 10, 983–995.

    Article  PubMed  CAS  Google Scholar 

  • Tenenbein, M., & Israels, S. J. (1988). Early coagulopathy in severe iron poisoning. Journal of Pediatrics, 113, 695–697.

    Article  PubMed  CAS  Google Scholar 

  • Tenenbein, M., Littman, C., & Stimpson, R. E. (1990). Gastrointestinal pathology in adult iron overdose. Journal of Toxicology and Clinical Toxicology, 28, 311–320.

    Article  CAS  Google Scholar 

  • Tenenbein, M., Kowalski, S., & Sienko, A. (1992). Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet, 339, 669–701.

    Article  Google Scholar 

  • Tenenbein, M. (1997). Position statement: Whole bowel irrigation. American academy of clinical toxicology; European association of poisons centres and clinical toxicologists. Journal of Toxicology and Clinical Toxicology, 35, 753–762.

    Article  CAS  Google Scholar 

  • Teucher, B., Olivares, M., & Cori, H. (2004, November). Enhancers of iron absorption: Ascorbic acid and other organic acids. International Journal for Vitamin and Nutrition Research, 74(6), 404–419.

    Article  Google Scholar 

  • Tung, B. Y., & Kowdley, K. V. (1998). Clinical management of iron overload. Gastroenterology Clinics, 27(3), 637–654.

    PubMed  CAS  Google Scholar 

  • Ueno, K., Tanaka, K., Tsujimura, K., Morishima, Y., Iwashige, H., Yamazaki, K., et al. (1993, November). Impairment of cefdinir absorption by iron ion. Clinical Pharmacology and Therapeutics, 54(5), 473–475.

    Article  PubMed  CAS  Google Scholar 

  • Umbreit, J. (2005, March). Iron deficiency: A concise review. American Journal of Hematology, 78, 225–231.

    Article  PubMed  CAS  Google Scholar 

  • Vale, J. A. (1997). Position statement: Gastric lavage. American academy of clinical toxicology: European association of poisons centres and clinical toxicologists. Journal of Toxicology and Clinical Toxicology, 35, 711–719.

    Article  CAS  Google Scholar 

  • Van Orden, H. E., & Hagemann, T. M. (2006). Deferasirox-An oral agent for chronic iron overload. Annals of Pharmacotherapy, 40, 1110–1117.

    Article  Google Scholar 

  • Van Wyck, D. B. (1999, August). Efficacy and adverse effects of oral iron supplements. Seminars in Dialysis, 12(4), 235–236.

    Article  Google Scholar 

  • Van Wyck, D. B., Cavallo, G., Spinowitz, B. S., Adhikarla, R., Gagnon, S., Charytan, C., et al. (2000, July). Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. American Journal of Kidney Diseases, 36(1), 88–97.

    Article  PubMed  Google Scholar 

  • Vernon, D. D., Banner, W., & Dean, J. M. (1989). Hemodynamic effects of experimental iron poisoning. Annals of Emergency Medicine, 18, 863–866.

    Article  PubMed  CAS  Google Scholar 

  • Villalobos, D. (1992). Reliability of urine color changes after deferoxamine challenge. Veterinary and Human Toxicology, 34, 330.

    Google Scholar 

  • Voskaridou, E., Douskou, M., & Terpos, E. (2004). Magnetic resonance imaging in the evaluation of iron overload in patients with beta-thalassemia and sickle cell disease. British Journal of Haematology, 126, 736–742.

    Article  PubMed  CAS  Google Scholar 

  • Walker, S. E., Paton, T. W., Cowan, D. H., & Manuel, M. A. (1989, September 15). Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. Canadian Medical Association Journal, 141, 543–547.

    PubMed  CAS  Google Scholar 

  • Watson Pharma. (2006a, September). Ferrlecit (package insert). Corona, CA.

    Google Scholar 

  • Watson Pharma. (2006b, March). Infed (package insert). Morristown, NJ.

    Google Scholar 

  • Weiss, B., Alkon, E., & Weindlar, F. (1993). Toddler deaths resulting from ingestion of iron supplements – Los Angeles, 1992–1993. Morbidity and Mortality Weekly Report, 42, 111–113.

    Google Scholar 

  • Westlin, W. F. (1971). Deferoxamine as a chelating agent. Clinical Toxicology, 4, 597–602.

    Article  PubMed  CAS  Google Scholar 

  • Whittaker, P. (1998, August). Iron and zinc interactions in humans. American Journal of Clinical Nutrition, 68(Suppl. 2), 442S–446S.

    PubMed  CAS  Google Scholar 

  • Witzleben, C. L., & Chaffey, N. J. (1966). Acute ferrous sulphate poisoning: A histochemical study of its effects on the liver. Archives of Pathology and Laboratory Medicine, 82, 454–460.

    CAS  Google Scholar 

  • Wood, J. C. (2007). Diagnosis and management of transfusion iron overload: The role of imaging. American Journal of Hematology, 82, 1132–1135.

    Article  PubMed  CAS  Google Scholar 

  • Wythe, E. T., Osterloh, J. D., & Becker, C. E. (1986). The reliability of serum iron levels after deferoxamine treatment: An in vitro study. Veterinary and Human Toxicology, 28, 478.

    Google Scholar 

  • Yonker, J., Banner, W., & Picchioni, A. (1980). Absorption characteristics of iron and deferoxamine onto charcoal. Veterinary and Human Toxicology, 2 2(S2), 75.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK, USA

    Tracy M. Hagemann PHARMD & Teresa V. Lewis PHARMD, BCPS

Authors
  1. Tracy M. Hagemann PHARMD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teresa V. Lewis PHARMD, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Psychology, Bar-Ilan University, Ramat Gan, 52900, Israel

    Shlomo Yehuda

  2. Dept. Psychology, Boston University, Cummington St. 64, Boston, 02215-2407, USA

    David I. Mostofsky

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hagemann, T.M., Lewis, T.V. (2009). Iron as a Drug and Drug–Drug Interactions. In: Yehuda, S., Mostofsky, D. (eds) Iron Deficiency and Overload. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59745-462-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-462-9_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-934115-22-0

  • Online ISBN: 978-1-59745-462-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation